Lobaplatin

Summary

Lobaplatin (CHEMBL4594256) is a phase-3 clinical-stage small molecule; indicated across 9 conditions including hepatocellular carcinoma and carcinoma of esophagus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 9 conditions
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594256
Name	Lobaplatin
Type	Small molecule
Max phase	3

Also known as: Lobaplatin, Lobaplatine, Lobaplatino, NSC-741422, LOBAPLATINE, LOBAPLATIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
carcinoma of esophagus	3	MONDO:0019086	EFO:0002916
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
nasopharyngeal neoplasm	2	MONDO:0005375	EFO:0004252
breast neoplasm	2	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE2	10
PHASE3	5
PHASE4	2
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07093931	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT03413436	PHASE4	COMPLETED	Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
NCT05780294	PHASE3	NOT_YET_RECRUITING	A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT01034683	PHASE3	UNKNOWN	Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma
NCT02099396	PHASE2/PHASE3	UNKNOWN	A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma
NCT02301091	PHASE3	UNKNOWN	Combine TACE and RFA Versus TACE Alone for HCC With PVTT
NCT05701436	PHASE3	UNKNOWN	Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
NCT05766605	PHASE3	UNKNOWN	Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
NCT04845490	PHASE2	NOT_YET_RECRUITING	Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
NCT06714383	PHASE2	RECRUITING	Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
NCT01483300	PHASE2	UNKNOWN	Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer
NCT03117257	PHASE2	UNKNOWN	Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN
NCT03210389	PHASE2	UNKNOWN	A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
NCT03700359	PHASE2	UNKNOWN	A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
NCT04808466	PHASE2	UNKNOWN	Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
NCT05546255	PHASE2	UNKNOWN	Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
NCT06170697	PHASE2	UNKNOWN	Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
NCT06198465	PHASE2	UNKNOWN	Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
NCT03188497	PHASE1	COMPLETED	Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).